Cronin, O., Forsyth, L., Goodman, K., Lewis, S. C., Keerie, C., Walker, A., Porteous, M., Cetnarskyj, R., Ranganath, L. R., Selby, P. L., Hampson, G., Chandra, R., Ho, S., Tobias, J. H., Young-Min, S., McKenna, M. J., Crowley, R. K., Fraser, W. D., Gennari, L., Nuti, R., Brandi, M. L., Del Pino-Montes, J., Devogelaer, J., Durnez, A., Isaia, G., Di Stefano, M., Guañabens, N., Blanch, J., Seibel, M. J., Walsh, J. P., Kotowicz, M. A., Nicholson, G. C., Duncan, E. L., Major, G., Horne, A., Gilchrist, N. L., Boers, M., Murray, G. D., Charnock, K., Wilkinson, D., Russell, R. G. G., & Ralston, S. H. (2019). zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone. BMJ open, 9(9), . http://access.bl.uk/ark:/81055/vdc_100135133782.0x000009